Improving drug discovery through advanced protein binding methods
Official title: Research and cloud deployment of enhanced sampling methods in MovableType
Funded at Quantumbio, INC. · NIH-10994631 · Data updated 2026-11-12
This study is exploring a new way to help scientists design better medicines by understanding how proteins interact with other molecules, making it easier to find effective treatments for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Quantumbio, INC. NIH-funded |
| Lab location | 1 site (State College, UNITED STATES) |
| Project start | June 1, 2023 |
| Project end | November 30, 2025 |
| Funding year | 2025 |
| Award (this year) | $654,406 |
| NIH project number | 5R44GM148103-03 |
| Project ID | NIH-10994631 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with conditions that could benefit from new drug therapies targeting specific protein interactions.
✕Less likely to help
Patients with conditions that do not involve protein-ligand interactions or those who are not seeking new drug therapies may not benefit from this research.
What this research studies
This research focuses on enhancing the understanding of how proteins bind to ligands, which is crucial for drug discovery. By utilizing a novel method called MovableType, the research aims to combine advanced molecular dynamics techniques with improved computational methods to accurately design new drug molecules. This approach seeks to streamline the drug development process by identifying effective compounds more efficiently, ultimately leading to better treatment options for patients. The research will leverage cloud-based computing to facilitate complex calculations and simulations.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective and targeted medications for various diseases.
How similar studies have gone: Previous research in computational biology and drug discovery has shown promising results using similar advanced molecular dynamics approaches.
Where this research is happening
-
Quantumbio, INC.
State College, United States Active
Researchers
- Principal investigator: Westerhoff, Lance M — Quantumbio, INC.
- Study coordinator: Westerhoff, Lance M
Related research
Other NIH-funded projects on the same topics.
-
Unified toolkit to refine protein structures with AI help for drug design
A project at Quantumbio, Inc. aims to use AI-augmented methods to better refine protein structures and their flexible parts to improve drug discovery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.